5
Sysmex launches fully automated HISCL HIT IgG Assay Kit to enhance heparin-induced thrombocytopenia (HIT) diagnosis accuracy and speed across EMEA
One document
more
Releases about Krankheit
Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ACOU085 is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across ...
moreThe Virchow Prize 2026 Awarded for Pioneering Work on Ebola, Advancing Global Epidemic Preparedness and Fostering Global Solidarity
moreEuropäischer Rechnungshof - European Court of Auditors
Koronakriisin jälkeinen miljardien eurojen arvoinen EU:n elpymisrahasto ei ole riittävän avoin
moreTechnische Universität München
Stem Cell Research: Reading Genetic Activity from Living Cells without Destroying Them
TECHNICAL UNIVERSITY OF MUNICH PRESS RELEASE Tool for Better Control of Stem Cell Development Reading Genetic Activity from Living Cells without Destroying Them - Multi-day gene activity profiles from the same cells - Long-term analysis of cell communication in mixed cultures - Potential applications in organoids and tumor microenvironments Until now, studying the ...
moreVITUS Privatklinik Prof. Dr. Stehling GmbH
First Clinical Analysis of Electrochemotherapy in Prostate Cancer Shows 93% Response
OFFENBACH, Germany (ots) - Vitus Privatklinik reports the first and largest clinical cohort of electrochemotherapy in prostate cancer. Vitus Privatklinik published the first clinical analysis of electrochemotherapy in prostate cancer, involving 144 patients treated between 2017 and 2024. The report is the largest dataset to date on this treatment. Radical prostatectomy ...
more
- 2
Press Release: STADA’s Strong Growth Journey Continues in 2025
One documentmore 100,000 Participants Screened for Early-Stage Type 1 Diabetes in the EDENT1FI Project
EDENT1FI (“European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception”), a research project led by Prof. Anette-Gabriele Ziegler from Helmholtz Munich and Prof. Chantal Mathieu from the KU Leuven, has reached an important milestone toward its goal, having screened 100,000 of the more than 200,000 children and adolescents ...
moreGrünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
Aachen, Germany & Yeoju, South Korea (ots) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will ...
more- 3
Medi-Globe Launches mAI Companion® - the World’s First Real‑Time AI Assistant for Pancreatic EUS, Co‑Developed with IHU Strasbourg / Now MDR CE‑Marked and Available for Clinical Use in Europe
more Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
moreEuropäischer Rechnungshof - European Court of Auditors
EU’s ambitious plan to combat cancer suffers from uncertainty
more
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
morePress Release: STADA invests more than €85m in Saudi Arabia manufacturing hub
One documentmorePress Release: STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
One documentmoreEuropäischer Rechnungshof - European Court of Auditors
Koronakriisin jälkeinen EU:n 650 miljardin euron elpymisrahasto: varoja suojataan petoksilta hajanaisesti
moreGrünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
moreServier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Suresnes, France (ots/PRNewswire) - - Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. - Growth over the financial year was driven by increased sales in oncology, particularly in the United States. - Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. - Achieving 2025 ...
more
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength
morePress Release: Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
One documentmoreXlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
morePress Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
3 DocumentsmoreAsklepios Kliniken GmbH & Co. KGaA
Hessian Minister President Boris Rhein presents the Broermann Medical Innovation Award
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
moreEuropäischer Rechnungshof - European Court of Auditors
Μικρό το όφελος για τις επιχειρήσεις της ΕΕ από τα δισεκατομμύρια που διατέθηκαν για την ανάκαμψη από την πανδημία
more
Europäischer Rechnungshof - European Court of Auditors
Koronapandemiasta toipumiseen osoitetuilla miljardeilla olisi voitu auttaa EU:n yrityksiä enemmänkin
moreEuropäischer Rechnungshof - European Court of Auditors
Coronamiljarderna kunde ha gjort mer för EU:s företag
moreEuropäischer Rechnungshof - European Court of Auditors
Paransivatko koronapandemiasta toipumiseen osoitetut miljardit EU:n liiketoimintaympäristöä? (Kutsu tiedotustilaisuuteen)
Kutsu tiedotustilaisuuteen 27. lokakuuta 2025 Paransivatko koronapandemiasta toipumiseen osoitetut miljardit EU:n liiketoimintaympäristöä? - Tiedotustilaisuus verkossa maanantaina 27. lokakuuta klo 10 00 Keski-Euroopan aikaa ...
moreEuropäischer Rechnungshof - European Court of Auditors
Har alla miljarder som gått till återhämtningen efter covid förbättrat EU:s företagsklimat? (Pressinbjudan)
Pressinbjudan till den 27 oktober 2025 Har alla miljarder som gått till återhämtningen efter covid förbättrat EU:s företagsklimat? - Presskonferens online måndagen den 27 oktober kl. 10.00 CET. - Offentliggörande samma ...
moreLetter of Intent for strategic partnership / Vaccentis and TrueMed join forces to advance cancer vaccine
Zurich (ots) - Vaccentis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner. Accelerating cancer vaccine against renal cell carcinoma The aim of this letter of intent is to ...
moreMaP Toolbox: Your Hub for Master Protocol Clinical Trials
more
123456789Next